10-Q - COMPASS Pathways plc (0001816590) (Filer)

Thu, May 8, 10:39 AM (11 days ago)

### Summary of Compass Pathways plc (CMPS) Q1 2025 Financial Performance **Revenue and Profit Margins:** - **Revenue:** No revenue reported as the company is still in the clinical stage. - **Net Loss:** $17.9 million for Q1 2025, compared to $35.2 million for Q1 2024. - **Gross Margin:** Not applicable due to no revenue. - **Operating Margin:** Not applicable due to no revenue. **Cash Flow:** - **Operating Cash Flow:** Negative $45.66 million for Q1 2025, compared to negative $20.83 million for Q1 2024. - **Investing Cash Flow:** Not provided. - **Financing Cash Flow:** Positive $140.36 million for Q1 2025, compared to $63.51 million for Q1 2024. **Earnings Changes:** - **EPS:** Negative $0.20 for Q1 2025, compared to negative $0.55 for Q1 2024. - **Net Income:** Negative $17.86 million for Q1 2025, compared to negative $35.19 million for Q1 2024. **Quarterly Performance Discussion:** - **Revenue:** No revenue generated as the company is in the clinical stage. - **Expenses:** Significant increase in research and development expenses due to advancing late-stage COMP360 clinical trials. - **Cash Flow:** Positive financing cash flow due to proceeds from the 2025 Financing and exercise of warrants. **Trends and Uncertainties:** - **Financial Health:** The company has sufficient cash to fund operations through the planned 26-week data read-out from the COMP006 study in the second half of 2026. - **Operational Impact:** The company is dependent on the successful development and commercialization of COMP360. **Future Operations Impact:** - **Revenue Growth:** Dependent on regulatory approval and commercialization of COMP360. - **Expense Management:** Continued increase in expenses due to clinical trials and commercialization efforts. - **Cash Flow:** Positive financing activities but negative operating cash flow due to high expenses.